Compare Stocks: HURA, ARTV, CAPR, and ENTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$10.22 -1.9%	$10.67	$2.22 ▼ $14.53	$499.66M	2.18	268,976 shs	228,434 shs
CAPR Capricor Therapeutics	$8.37 +0.8%	$11.05	$2.96 ▼ $40.37	$486.62M	0.72	7.65 million shs	2.07 million shs
ENTX Entera Bio	$2.84 +1.8%	$2.67	$0.91 ▼ $4.20	$493.69M	1.38	360,566 shs	187,599 shs
HURA TuHURA Biosciences	$2.05 +1.0%	$2.19	$0.41 ▼ $3.43	$130.64M	-0.02	206,505 shs	113,948 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-8.67%	-9.56%	+19.67%	+278.52%
CAPR Capricor Therapeutics	0.00%	-10.96%	+98.81%	-67.56%	+32.23%
ENTX Entera Bio	0.00%	-5.33%	-1.05%	+130.89%	+52.69%
HURA TuHURA Biosciences	0.00%	-4.21%	-10.87%	-11.64%	-13.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$10.22 -1.9%	$10.67	$2.22 ▼ $14.53	$499.66M	2.18	268,976 shs	228,434 shs
CAPR Capricor Therapeutics	$8.37 +0.8%	$11.05	$2.96 ▼ $40.37	$486.62M	0.72	7.65 million shs	2.07 million shs
ENTX Entera Bio	$2.84 +1.8%	$2.67	$0.91 ▼ $4.20	$493.69M	1.38	360,566 shs	187,599 shs
HURA TuHURA Biosciences	$2.05 +1.0%	$2.19	$0.41 ▼ $3.43	$130.64M	-0.02	206,505 shs	113,948 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-8.67%	-9.56%	+19.67%	+278.52%
CAPR Capricor Therapeutics	0.00%	-10.96%	+98.81%	-67.56%	+32.23%
ENTX Entera Bio	0.00%	-5.33%	-1.05%	+130.89%	+52.69%
HURA TuHURA Biosciences	0.00%	-4.21%	-10.87%	-11.64%	-13.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	281.60% Upside
CAPR Capricor Therapeutics	2.18	Hold	$29.15	248.27% Upside
ENTX Entera Bio	2.00	Hold	$9.00	216.90% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	339.02% Upside

Current Analyst Ratings Breakdown

Latest HURA, ARTV, CAPR, and ENTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.50
7/30/2026	CAPR Capricor Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/28/2026	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00
7/27/2026	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	1,998.62	N/A	N/A	$4.48 per share	2.28
CAPR Capricor Therapeutics	$22.27M	21.85	N/A	N/A	$5.53 per share	1.51
ENTX Entera Bio	$40K	12,341.93	N/A	N/A	$0.29 per share	9.79
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)

Latest HURA, ARTV, CAPR, and ENTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
CAPR Capricor Therapeutics	N/A	7.35	7.35
ENTX Entera Bio	N/A	8.98	8.98
HURA TuHURA Biosciences	0.20	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
CAPR Capricor Therapeutics	21.68%
ENTX Entera Bio	14.11%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
CAPR Capricor Therapeutics	9.20%
ENTX Entera Bio	10.57%
HURA TuHURA Biosciences	6.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	48.89 million	48.01 million	N/A
CAPR Capricor Therapeutics	101	58.14 million	52.79 million	Optionable
ENTX Entera Bio	20	173.83 million	155.46 million	Optionable
HURA TuHURA Biosciences	N/A	63.73 million	59.87 million	N/A

HURA, ARTV, CAPR, and ENTX Headlines

Recent News About These Companies

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts

September 12 at 6:13 AM | marketbeat.com

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | prnewswire.com

BlackRock Inc. Purchases New Shares in TuHURA Biosciences, Inc. $HURA

September 7, 2026 | marketbeat.com

TuHURA Biosciences draws additional funds from credit facility

September 4, 2026 | tipranks.com

Equities Analysts Offer Predictions for HURA FY2026 Earnings

August 28, 2026 | marketbeat.com

HURA: Milestone Progression Over Next 12 Months

August 26, 2026 | finance.yahoo.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

August 21, 2026 | tipranks.com

Q3 EPS Forecast for TuHURA Biosciences Decreased by Analyst

August 21, 2026 | marketbeat.com

What is HC Wainwright's Estimate for HURA Q1 Earnings?

August 20, 2026 | marketbeat.com

TuHURA Biosciences' (HURA) "Market Outperform" Rating Reaffirmed at Citizens Jmp

August 18, 2026 | marketbeat.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 18, 2026 | marketbeat.com

TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

August 14, 2026 | marketbeat.com

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

August 14, 2026 | marketbeat.com

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

August 14, 2026 | prnewswire.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

August 13, 2026 | tipranks.com

TuHURA Biosciences Expands Revolving Credit Facility Utilization

July 29, 2026 | tipranks.com

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

July 22, 2026 | prnewswire.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

July 7, 2026 | tipranks.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets ...

June 16, 2026 | finanznachrichten.de

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood ...

June 15, 2026 | finance.yahoo.com

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

June 15, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HURA, ARTV, CAPR, and ENTX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$10.22 -0.20 (-1.92%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$10.20 -0.02 (-0.20%)

As of 09/11/2026 07:30 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Capricor Therapeutics NASDAQ:CAPR

$8.37 +0.07 (+0.84%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.40 +0.03 (+0.36%)

As of 09/11/2026 07:53 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Entera Bio NASDAQ:ENTX

$2.84 +0.05 (+1.79%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.84 0.00 (-0.18%)

As of 09/11/2026 07:30 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

TuHURA Biosciences NASDAQ:HURA

$2.05 +0.02 (+0.99%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.01 (+0.24%)

As of 09/11/2026 07:30 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, ARTV, CAPR, and ENTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, ARTV, CAPR, and ENTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, ARTV, CAPR, and ENTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HURA, ARTV, CAPR, and ENTX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Capricor Therapeutics NASDAQ:CAPR

Entera Bio NASDAQ:ENTX

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, ARTV, CAPR, and ENTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, ARTV, CAPR, and ENTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, ARTV, CAPR, and ENTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HURA, ARTV, CAPR, and ENTX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Capricor Therapeutics NASDAQ:CAPR

Entera Bio NASDAQ:ENTX

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools